# Study of Hepatitis Eradication Receiving Protease Inhibitor Administration

> **NCT03886077** · — · COMPLETED · sponsor: **Sentara Norfolk General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Coronary Artery Disease
- Morality

## Interventions

- **DRUG:** glecaprevir/pibrentasivir

## Key facts

- **NCT ID:** NCT03886077
- **Lead sponsor:** Sentara Norfolk General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-20
- **Primary completion:** 2024-12-20
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886077, "Study of Hepatitis Eradication Receiving Protease Inhibitor Administration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03886077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*